Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Platinum + Pemetrexed in T790M- Negative NSCLC Post-EGFR TKI
NCT03706287Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- Dec 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Sichuan Cancer Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03706287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03706287.